Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Operating Expenses (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Operating Expenses data on record, last reported at $39.8 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 1.45% year-over-year to $39.8 million; the TTM value through Dec 2025 reached $195.1 million, up 15.85%, while the annual FY2025 figure was $215.7 million, 28.03% up from the prior year.
  • Operating Expenses reached $39.8 million in Q4 2025 per AMPH's latest filing, down from $73.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $73.3 million in Q3 2025 and bottomed at $26.4 million in Q3 2021.
  • Average Operating Expenses over 5 years is $39.4 million, with a median of $37.7 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: fell 19.94% in 2021, then soared 55.41% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $32.0 million in 2021, then increased by 4.23% to $33.3 million in 2022, then grew by 26.47% to $42.2 million in 2023, then decreased by 6.99% to $39.2 million in 2024, then grew by 1.45% to $39.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $39.8 million in Q4 2025, $73.3 million in Q3 2025, and $34.1 million in Q2 2025.